A data set from the ECOG E1684 trial comparing the high-dose interferon alfa-2b (IFN) therapy with the observation in resected high-risk melanoma patients. The study results were described in Kirkwood et al. (1996) doi:10.1200/JCO.1996.14.1.7.
E1684A data frame with 262 rows and 8 variables:
time to relapse in years
censoring indicator for time to relapse, 0 = did not relapse, 1 = relapsed
time to death in years
censoring indicator for time to death, 0 = alive, 1 = dead
treatment indicator, 0 = observation, 1 = high-dose IFN
gender indicator, 0 = male, 1 = female
patient age in years
indicator for having more than one cancerous lymph node, 0 = with one or no cancerous lymph nodes, 1 = with more than one cancerous lymph node
Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., and Blum, R. H. (1996). Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684. Journal of Clinical Oncology, 14(1), 7–17.